Vericiguat + Placebo
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metabolic Syndrome
Conditions
Metabolic Syndrome, Coronary Microvascular Dysfunction
Trial Timeline
Jun 16, 2023 → Nov 18, 2025
NCT ID
NCT05711719About Vericiguat + Placebo
Vericiguat + Placebo is a phase 2 stage product being developed by Merck for Metabolic Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT05711719. Target conditions include Metabolic Syndrome, Coronary Microvascular Dysfunction.
What happened to similar drugs?
19 of 20 similar drugs in Metabolic Syndrome were approved
Approved (19) Terminated (4) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05711719 | Phase 2 | Completed |
| NCT05420012 | Approved | Completed |
| NCT05093933 | Phase 3 | Completed |
Competing Products
20 competing products in Metabolic Syndrome